Details of Disease

Disease Name

Neurodegenerative disease

cerebral degeneration disease; degenerative disease; central nervous system neurodegenerative disorder; brain degeneration; neurodegenerative disease; central nervous system degenerative disorder; degenerative disorder of central nervous system

Definition

A disorder of the central nervous system characterized by gradual and progressive loss of neural tissue and neurologic function.|Editor notes: DO treats this as two diseases

Disease Hierarchy

DISEP2HK: Central and peripheral nervous disease

DISM20FF: Neurodegenerative disease

Disease Identifiers

MONDO ID

MONDO_0005559

MESH ID

D009410

UMLS CUI

C0027746

MedGen ID

17999

HPO ID

HP:0002180

General Information of Disease (ID: DISM20FF)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 63 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APOE	TTKS9CB	Limited	Biomarker	[1]
CD9	TTZEIBV	Limited	Biomarker	[1]
DDC	TTN451K	Limited	Biomarker	[1]
ETS2	TT9AH0M	Limited	Biomarker	[1]
NGF	TTDN3LF	Limited	Therapeutic	[2]
PSEN1	TTZ3S8C	Limited	Biomarker	[1]
SOD1	TTP9K3Q	Limited	Biomarker	[3]
SLC5A6	TT61XTV	Disputed	Biomarker	[4]
ADORA1	TTK25J1	moderate	Therapeutic	[5]
ADRA1B	TTBRKXS	moderate	Biomarker	[6]
ARG2	TTV1AG6	moderate	Biomarker	[7]
ATXN3	TT6A17J	moderate	Biomarker	[8]
BAK1	TTFM7V0	moderate	Biomarker	[9]
BAX	TTQ57WJ	moderate	Therapeutic	[10]
CASP3	TTPF2QI	moderate	Biomarker	[11]
CD4	TTN2JFW	moderate	Biomarker	[12]
CD44	TTWFBT7	moderate	Biomarker	[13]
CDH1	TTLAWO6	moderate	Biomarker	[14]
CDH2	TT1WS0T	moderate	Biomarker	[14]
CDK5R1	TTBYM6V	moderate	Biomarker	[15]
CNTF	TTGEM5Q	moderate	Therapeutic	[16]
DDIT4	TTVEOY6	moderate	Therapeutic	[17]
EPO	TTQG4NR	moderate	Therapeutic	[18]
EPOR	TTAUX24	moderate	Therapeutic	[18]
F2	TT6L509	moderate	Biomarker	[19]
FGF2	TTGKIED	moderate	Therapeutic	[20]
GHRL	TT1OCL0	moderate	Therapeutic	[21]
GRIN2D	TT5POTG	moderate	Biomarker	[22]
GRM4	TTICZ1O	moderate	Therapeutic	[23]
GRN	TT0LWE3	moderate	Therapeutic	[24]
IGF1	TTT6LOU	moderate	Therapeutic	[20]
IGF2	TTE8WGO	moderate	Therapeutic	[25]
KCNJ4	TTXF0ZW	moderate	Therapeutic	[26]
KCNJ6	TTTIBVP	moderate	Biomarker	[27]
LEP	TTBJEZ5	moderate	Therapeutic	[28]
LRRK2	TTK0FEA	moderate	Biomarker	[29]
MAPK1	TT4TQBX	moderate	Biomarker	[22]
MAPK3	TT1MG9E	moderate	Biomarker	[22]
NGFR	TTEDJN4	moderate	Biomarker	[30]
NOS1	TTZUFI5	moderate	Biomarker	[31]
NTF3	TTZHKV9	moderate	Therapeutic	[32]
OGG1	TTRU01G	moderate	Biomarker	[33]
OTC	TT5KIO9	moderate	Biomarker	[34]
PLAT	TTXAGYU	moderate	Biomarker	[22]
PPARG	TTT2SVW	moderate	Therapeutic	[35]
SIRT1	TTUF2HO	moderate	Therapeutic	[15]
SLC18A2	TTNZRI3	moderate	Biomarker	[36]
SLC1A2	TT2F078	moderate	Therapeutic	[37]
SNCA	TT08OSU	moderate	Biomarker	[38]
TGFA	TTTLQFR	moderate	Therapeutic	[39]
TH	TTUHP71	moderate	Biomarker	[6]
XDH	TT7RJY8	moderate	Biomarker	[40]
APP	TTE4KHA	Strong	Biomarker	[41]
BDNF	TTSMLOH	Strong	Therapeutic	[42]
BECN1	TT5M7LN	Strong	Biomarker	[43]
CHRNA7	TTLA931	Strong	Therapeutic	[44]
CHRNB2	TT5KPZR	Strong	Therapeutic	[44]
CNR1	TT6OEDT	Strong	Therapeutic	[45]
DAG1	TT4X7PG	Strong	Biomarker	[46]
HSPA5	TTW26OG	Strong	Biomarker	[43]
NTF4	TTIM2WO	Strong	Therapeutic	[47]
SLC1A1	TTG2A6F	Strong	Biomarker	[48]
SLC6A3	TTVBI8W	Strong	Biomarker	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 63 DTT(s)

This Disease Is Related to 23 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
SCYL1	OTQ0IN7P	Limited	CausalMutation	[50]
DCTN1	OT5B51FJ	Disputed	Genetic Variation	[51]
AGTPBP1	OTR92JFR	moderate	Biomarker	[52]
APLP2	OTTFE53M	moderate	Biomarker	[53]
ATRN	OTTCLOPV	moderate	Biomarker	[54]
CP	OTM8JE4Y	moderate	Therapeutic	[55]
EIF2S1	OTM0GDTP	moderate	Biomarker	[56]
LRP8	OTZ71YV2	moderate	Biomarker	[57]
MPZ	OTAR2YXH	moderate	Biomarker	[58]
OTX2	OTTV05B1	moderate	Biomarker	[59]
PANK2	OTFBW889	moderate	Biomarker	[60]
PINK1	OT50NR57	moderate	Biomarker	[34]
PRKN	OTJBN41W	moderate	Biomarker	[61]
PTPN5	OT2H1KDK	moderate	Biomarker	[62]
SELENOP	OT02B8IR	moderate	Biomarker	[57]
TSC2	OT47LWI9	moderate	Biomarker	[63]
ANK2	OTWB4R1Y	Strong	Biomarker	[64]
ATP13A2	OTKWBUGK	Strong	Biomarker	[65]
EEF1A2	OT9Z23K5	Strong	Biomarker	[66]
GARS1	OT5B6R9Y	Strong	Genetic Variation	[67]
MAP1LC3A	OTPMGIU4	Strong	Biomarker	[43]
ERLIN2	OT551BVG	Definitive	Biomarker	[68]
IRF2BPL	OTV8MNT1	Definitive	Autosomal dominant	[69]
------------------------------------------------------------------------------------


⏷ Show the Full List of 23 DOT(s)

References

1	ETS2 regulating neurodegenerative signaling pathway of human neuronal (SH-SY5Y) cells exposed to single and repeated low-dose sarin (GB). Chem Res Toxicol. 2009 Jun;22(6):990-6.
2	Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice.PLoS One. 2012;7(5):e37555. doi: 10.1371/journal.pone.0037555. Epub 2012 May 30.
3	Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1GA ALS mice: overlapping effects or limited therapeutic opportunity?.Orphanet J Rare Dis. 2014 May 21;9:78. doi: 10.1186/1750-1172-9-78.
4	Mutations in SLC5A6 associated with brain, immune, bone, and intestinal dysfunction in a young child. Hum Genet. 2017 Feb;136(2):253-261. doi: 10.1007/s00439-016-1751-x. Epub 2016 Nov 30.
5	Decreased extracellular adenosine levels lead to loss of hypoxia-induced neuroprotection after repeated episodes of exposure to hypoxia.PLoS One. 2013;8(2):e57065. doi: 10.1371/journal.pone.0057065. Epub 2013 Feb 21.
6	Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.J Neurochem. 2003 Jul;86(2):413-21. doi: 10.1046/j.1471-4159.2003.01867.x.
7	Retinal Neuroprotection From Optic Nerve Trauma by Deletion of Arginase 2.Front Neurosci. 2018 Dec 20;12:970. doi: 10.3389/fnins.2018.00970. eCollection 2018.
8	Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila.Cell. 1998 Jun 12;93(6):939-49. doi: 10.1016/s0092-8674(00)81200-3.
9	Therapeutic potential of BAK gene silencing in aluminum induced neural cell degeneration.J Inorg Biochem. 2009 Nov;103(11):1514-20. doi: 10.1016/j.jinorgbio.2009.06.010. Epub 2009 Aug 14.
10	Bax gene silencing: a potential intervention in aluminum-induced neural cell death.J Biol Regul Homeost Agents. 2010 Jan-Mar;24(1):7-17.
11	Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.J Neurosci. 2004 Mar 3;24(9):2182-90. doi: 10.1523/JNEUROSCI.5275-03.2004.
12	Novel role of human CD4 molecule identified in neurodegeneration.Nat Med. 1998 Apr;4(4):441-6. doi: 10.1038/nm0498-441.
13	Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice.Exp Neurol. 2004 Jul;188(1):1-10. doi: 10.1016/j.expneurol.2004.03.019.
14	Differential regulation of cadherins and catenins during axonal reorganization in the adult rat CNS.J Neuropathol Exp Neurol. 2002 Oct;61(10):903-13. doi: 10.1093/jnen/61.10.903.
15	SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.EMBO J. 2007 Jul 11;26(13):3169-79. doi: 10.1038/sj.emboj.7601758. Epub 2007 Jun 21.
16	Delayed neurotrophic treatment preserves nerve survival and electrophysiological responsiveness in neomycin-deafened guinea pigs.J Neurosci Res. 2004 Oct 1;78(1):75-86. doi: 10.1002/jnr.20239.
17	RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.J Neurosci. 2006 Sep 27;26(39):9996-10005. doi: 10.1523/JNEUROSCI.3292-06.2006.
18	Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons.Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9848-53. doi: 10.1073/pnas.0901840106. Epub 2009 Jun 3.
19	Degeneration of dopaminergic neurons induced by thrombin injection in the substantia nigra of the rat is enhanced by dexamethasone: role of monoamine oxidase enzyme.Neurotoxicology. 2010 Jan;31(1):55-66. doi: 10.1016/j.neuro.2009.12.001. Epub 2009 Dec 5.
20	Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide.Cell Death Differ. 1998 Oct;5(10):911-9. doi: 10.1038/sj.cdd.4400439.
21	Ghrelin protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats.Neurosci Lett. 2009 Mar 27;453(1):58-61. doi: 10.1016/j.neulet.2009.01.067. Epub 2009 Jan 30.
22	NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity.Cell Death Differ. 2010 May;17(5):860-71. doi: 10.1038/cdd.2009.172. Epub 2009 Nov 13.
23	Functional role of mGluR1 and mGluR4 in pilocarpine-induced temporal lobe epilepsy.Neurobiol Dis. 2007 Jun;26(3):623-33. doi: 10.1016/j.nbd.2007.03.003. Epub 2007 Mar 16.
24	Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling.Neurobiol Aging. 2011 Dec;32(12):2326.e5-16. doi: 10.1016/j.neurobiolaging.2011.06.017. Epub 2011 Aug 4.
25	Involvement of IGF-II receptors in the antioxidant and neuroprotective effects of IGF-II on adult cortical neuronal cultures.Biochim Biophys Acta. 2014 Jul;1842(7):1041-51. doi: 10.1016/j.bbadis.2014.03.010. Epub 2014 Mar 22.
26	Overexpression of Kir2.3 in PC12 cells resists rotenone-induced neurotoxicity associated with PKC signaling pathway.Biochem Biophys Res Commun. 2008 Sep 19;374(2):204-9. doi: 10.1016/j.bbrc.2008.07.003. Epub 2008 Jul 11.
27	Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation.J Cell Mol Med. 2004 Apr-Jun;8(2):213-22. doi: 10.1111/j.1582-4934.2004.tb00276.x.
28	Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization.J Biol Chem. 2008 Jan 18;283(3):1754-1763. doi: 10.1074/jbc.M703753200. Epub 2007 Nov 9.
29	Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila.J Neurosci. 2009 Sep 9;29(36):11257-62. doi: 10.1523/JNEUROSCI.2375-09.2009.
30	p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure.J Neurosci. 1999 Aug 15;19(16):6887-96. doi: 10.1523/JNEUROSCI.19-16-06887.1999.
31	[Nitric oxide-induced neurotoxicity versus neuroprotection; relationship with selective motor neuronal death].Rinsho Shinkeigaku. 1999 Dec;39(12):1244-7.
32	Neurotrophin protection against toxicity induced by low potassium and nitroprusside in cultured cerebellar granule neurons.J Neurochem. 1997 Jan;68(1):68-77. doi: 10.1046/j.1471-4159.1997.68010068.x.
33	Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies.Redox Biol. 2016 Apr;7:30-38. doi: 10.1016/j.redox.2015.11.005. Epub 2015 Nov 18.
34	Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress.Neuropharmacology. 2014 Feb;77:350-7. doi: 10.1016/j.neuropharm.2013.10.009. Epub 2013 Oct 23.
35	Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus.Brain Res. 2008 Mar 20;1200:146-58. doi: 10.1016/j.brainres.2008.01.047. Epub 2008 Jan 26.
36	Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.J Neurochem. 2008 Sep;106(5):2205-17. doi: 10.1111/j.1471-4159.2008.05568.x. Epub 2008 Jul 15.
37	GPR30 regulates glutamate transporter GLT-1 expression in rat primary astrocytes.J Biol Chem. 2012 Aug 3;287(32):26817-28. doi: 10.1074/jbc.M112.341867. Epub 2012 May 29.
38	Interaction between subclinical doses of the Parkinson's disease associated gene, -synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.Behav Brain Res. 2017 Jan 1;316:160-168. doi: 10.1016/j.bbr.2016.08.056. Epub 2016 Aug 29.
39	Transforming growth factor alpha treatment alters intracellular calcium levels in hair cells and protects them from ototoxic damage in vitro.Int J Dev Neurosci. 1997 Jul;15(4-5):553-62. doi: 10.1016/s0736-5748(96)00110-4.
40	Eugenol protects neuronal cells from excitotoxic and oxidative injury in primary cortical cultures.Neurosci Lett. 1997 Apr 4;225(2):93-6. doi: 10.1016/s0304-3940(97)00195-x.
41	Time course study of A formation and neurite outgrowth disruption in differentiated human neuroblastoma cells exposed to H2O2: protective role of autophagy. Toxicol In Vitro. 2013 Sep;27(6):1780-8. doi: 10.1016/j.tiv.2013.05.005. Epub 2013 May 29.
42	Brain-derived neurotrophic factor facilitates TrkB down-regulation and neuronal injury after status epilepticus in the rat hippocampus.J Neurochem. 2009 Oct;111(2):428-40. doi: 10.1111/j.1471-4159.2009.06342.x. Epub 2009 Aug 17.
43	Autophagy, and BiP level decrease are early key events in retrograde degeneration of motoneurons.Cell Death Differ. 2011 Oct;18(10):1617-27. doi: 10.1038/cdd.2011.24. Epub 2011 Mar 25.
44	Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by 7 and 2* nicotinic stimulation. Toxicol Sci. 2011 Sep;123(1):193-205. doi: 10.1093/toxsci/kfr163. Epub 2011 Jun 29.
45	Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death.Toxicol Appl Pharmacol. 2014 Jan 1;274(1):17-23. doi: 10.1016/j.taap.2013.10.028. Epub 2013 Nov 6.
46	Association of dystroglycan and laminin-2 coexpression with myelinogenesis in peripheral nerves.Med Electron Microsc. 2003 Dec;36(4):221-39. doi: 10.1007/s00795-003-0231-2.
47	Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures.Eur J Neurosci. 1996 Sep;8(9):1897-905. doi: 10.1111/j.1460-9568.1996.tb01333.x.
48	Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma.Cell Death Dis. 2017 Jul 13;8(7):e2934. doi: 10.1038/cddis.2017.341.
49	The role of dopamine transporter in selective toxicity of manganese and rotenone. Toxicology. 2008 Feb 28;244(2-3):249-56. doi: 10.1016/j.tox.2007.11.018. Epub 2007 Dec 3.
50	SCYL1 variants cause a syndrome with low -glutamyl-transferase cholestasis, acute liver failure, and neurodegeneration (CALFAN).Genet Med. 2018 Oct;20(10):1255-1265. doi: 10.1038/gim.2017.260. Epub 2018 Feb 8.
51	The G59S mutation in p150(glued) causes dysfunction of dynactin in mice.J Neurosci. 2007 Dec 19;27(51):13982-90. doi: 10.1523/JNEUROSCI.4226-07.2007.
52	The carboxypeptidase-like substrate-binding site in Nna1 is essential for the rescue of the Purkinje cell degeneration (pcd) phenotype.Mol Cell Neurosci. 2006 Oct;33(2):200-13. doi: 10.1016/j.mcn.2006.07.009. Epub 2006 Sep 6.
53	Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein.J Neurosci. 2002 Jan 15;22(2):365-76. doi: 10.1523/JNEUROSCI.22-02-00365.2002.
54	The neuroprotective role of attractin in neurodegeneration.Neurobiol Aging. 2007 Sep;28(9):1446-56. doi: 10.1016/j.neurobiolaging.2006.06.014. Epub 2006 Jul 24.
55	Increased vulnerability to rotenone-induced neurotoxicity in ceruloplasmin-deficient mice.Neurosci Lett. 2008 Nov 28;446(1):56-8. doi: 10.1016/j.neulet.2008.08.089. Epub 2008 Sep 11.
56	Phosphorylation of the alpha subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus.Biochem J. 2006 Jul 1;397(1):187-94. doi: 10.1042/BJ20051643.
57	Neurodegeneration in mice resulting from loss of functional selenoprotein P or its receptor apolipoprotein E receptor 2.J Neuropathol Exp Neurol. 2008 Jan;67(1):68-77. doi: 10.1097/NEN.0b013e318160f347.
58	Heterozygous P0 deficiency protects mice from vincristine-induced polyneuropathy.J Neurosci Res. 2006 Jul;84(1):37-46. doi: 10.1002/jnr.20873.
59	The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons.Brain. 2010 Jul;133(Pt 7):2022-31. doi: 10.1093/brain/awq142. Epub 2010 Jun 23.
60	Zinc accumulation in heterozygous mutants of fumble, the pantothenate kinase homologue of Drosophila.FEBS Lett. 2010 Jul 2;584(13):2942-6. doi: 10.1016/j.febslet.2010.05.029. Epub 2010 May 21.
61	Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.J Neurosci. 2007 Aug 8;27(32):8563-70. doi: 10.1523/JNEUROSCI.0218-07.2007.
62	Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase.J Neurosci. 2007 Mar 14;27(11):2999-3009. doi: 10.1523/JNEUROSCI.4913-06.2007.
63	Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.Neurobiol Dis. 2011 Jul;43(1):113-22. doi: 10.1016/j.nbd.2011.02.014. Epub 2011 Mar 17.
64	Selective disappearance of an axonal protein, 440-kDa ankyrinB, associated with neuronal degeneration induced by methylmercury.J Neurosci Res. 2003 Sep 15;73(6):831-9. doi: 10.1002/jnr.10715.
65	Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. J Neurosci Res. 2012 Dec;90(12):2306-16. doi: 10.1002/jnr.23112. Epub 2012 Jul 30.
66	Increased levels of statin, a marker of cell cycle arrest, in response to hippocampal neuronal injury.Brain Res Mol Brain Res. 1995 Dec 1;34(1):57-64. doi: 10.1016/0169-328x(95)00134-e.
67	Severe childhood SMA and axonal CMT due to anticodon binding domain mutations in the GARS gene.Neurology. 2006 Nov 14;67(9):1710-2. doi: 10.1212/01.wnl.0000242619.52335.bc.
68	Massive sequencing of 70 genes reveals a myriad of missing genes or mechanisms to be uncovered in hereditary spastic paraplegias.Eur J Hum Genet. 2017 Nov;25(11):1217-1228. doi: 10.1038/ejhg.2017.124. Epub 2017 Aug 23.
69	Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.